Cargando…
Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase
Gastric cancer (GC) is one of the most common cancers worldwide. In the clinical setting, the identification of HER2 overexpression in GC was a significant finding, as trastuzumab, an anti-HER2 drug, provides a survival advantage to HER2-positive GC patients. In HER2-postive GC, the dysregulation of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479539/ https://www.ncbi.nlm.nih.gov/pubmed/30959742 http://dx.doi.org/10.3390/ijms20071697 |
_version_ | 1783413368574443520 |
---|---|
author | Tokumaru, Yoshihisa Tajirika, Toshihiro Sugito, Nobuhiko Kuranaga, Yuki Shinohara, Haruka Tsujino, Takuya Matsuhashi, Nobuhisa Futamura, Manabu Akao, Yukihiro Yoshida, Kazuhiro |
author_facet | Tokumaru, Yoshihisa Tajirika, Toshihiro Sugito, Nobuhiko Kuranaga, Yuki Shinohara, Haruka Tsujino, Takuya Matsuhashi, Nobuhisa Futamura, Manabu Akao, Yukihiro Yoshida, Kazuhiro |
author_sort | Tokumaru, Yoshihisa |
collection | PubMed |
description | Gastric cancer (GC) is one of the most common cancers worldwide. In the clinical setting, the identification of HER2 overexpression in GC was a significant finding, as trastuzumab, an anti-HER2 drug, provides a survival advantage to HER2-positive GC patients. In HER2-postive GC, the dysregulation of PI3K/AKT and MAPK/ERK signaling pathways has been reported, and inhibition of these pathways is an important therapeutic strategy. MiR-143 is known to act as a tumor suppressor in several cancers, such as bladder cancer, breast cancer, colorectal cancer, and gastric cancer. In the current study, we developed a novel chemically-modified miR-143 and explored the functions of this synthetic miR-143 (syn-miR-143) in HER2-positive gastric cancer. The expression level of miR-143 was down-regulated in GC cell lines, including HER2-positive GC cell lines, MKN7, and KATO-III. The ectopic expression of miR-143 in those cell lines suppressed cell growth through systemic silencing of KRAS and its effector signaling molecules, AKT and ERK. Furthermore, syn-miR-143 indirectly down-regulated the expression of HER2, an upstream molecule of KRAS, through silencing DEAD/H-box RNA helicase 6 (DDX6), RNA helicase, which enhanced HER2 protein expression at the translational step in HER2-positive GC cells. These findings suggested that syn-miR-143 acted as a tumor suppressor through the impairment of KRAS networks including the DDX6. |
format | Online Article Text |
id | pubmed-6479539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64795392019-04-29 Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase Tokumaru, Yoshihisa Tajirika, Toshihiro Sugito, Nobuhiko Kuranaga, Yuki Shinohara, Haruka Tsujino, Takuya Matsuhashi, Nobuhisa Futamura, Manabu Akao, Yukihiro Yoshida, Kazuhiro Int J Mol Sci Article Gastric cancer (GC) is one of the most common cancers worldwide. In the clinical setting, the identification of HER2 overexpression in GC was a significant finding, as trastuzumab, an anti-HER2 drug, provides a survival advantage to HER2-positive GC patients. In HER2-postive GC, the dysregulation of PI3K/AKT and MAPK/ERK signaling pathways has been reported, and inhibition of these pathways is an important therapeutic strategy. MiR-143 is known to act as a tumor suppressor in several cancers, such as bladder cancer, breast cancer, colorectal cancer, and gastric cancer. In the current study, we developed a novel chemically-modified miR-143 and explored the functions of this synthetic miR-143 (syn-miR-143) in HER2-positive gastric cancer. The expression level of miR-143 was down-regulated in GC cell lines, including HER2-positive GC cell lines, MKN7, and KATO-III. The ectopic expression of miR-143 in those cell lines suppressed cell growth through systemic silencing of KRAS and its effector signaling molecules, AKT and ERK. Furthermore, syn-miR-143 indirectly down-regulated the expression of HER2, an upstream molecule of KRAS, through silencing DEAD/H-box RNA helicase 6 (DDX6), RNA helicase, which enhanced HER2 protein expression at the translational step in HER2-positive GC cells. These findings suggested that syn-miR-143 acted as a tumor suppressor through the impairment of KRAS networks including the DDX6. MDPI 2019-04-05 /pmc/articles/PMC6479539/ /pubmed/30959742 http://dx.doi.org/10.3390/ijms20071697 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tokumaru, Yoshihisa Tajirika, Toshihiro Sugito, Nobuhiko Kuranaga, Yuki Shinohara, Haruka Tsujino, Takuya Matsuhashi, Nobuhisa Futamura, Manabu Akao, Yukihiro Yoshida, Kazuhiro Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase |
title | Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase |
title_full | Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase |
title_fullStr | Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase |
title_full_unstemmed | Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase |
title_short | Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase |
title_sort | synthetic mir-143 inhibits growth of her2-positive gastric cancer cells by suppressing kras networks including ddx6 rna helicase |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479539/ https://www.ncbi.nlm.nih.gov/pubmed/30959742 http://dx.doi.org/10.3390/ijms20071697 |
work_keys_str_mv | AT tokumaruyoshihisa syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT tajirikatoshihiro syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT sugitonobuhiko syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT kuranagayuki syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT shinoharaharuka syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT tsujinotakuya syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT matsuhashinobuhisa syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT futamuramanabu syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT akaoyukihiro syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase AT yoshidakazuhiro syntheticmir143inhibitsgrowthofher2positivegastriccancercellsbysuppressingkrasnetworksincludingddx6rnahelicase |